Enara Bio

United Kingdom - Oxford, Oxfordshire

• 04/10/2024
• Series B
• $32,500,000

Enara Bio is shining a light on Dark Antigen® and T-cell biology to develop cancer immunotherapies designed to improve treatment outcomes for broad populations of cancer patients. Our pioneering EDAPT® platform enables us to discover novel cancer-specific antigens from previously uncharted genomic ‘dark matter’. The result is a growing database of Dark Antigens that can address the unmet need for cancer-specific targets that are homogenously expressed and highly prevalent in solid tumors. We are advancing multiple approaches to exploit these Dark Antigen targets, with an internal focus on TCR-directed immunotherapies, and additional therapeutic partnerships with Boehringer Ingelheim and another undisclosed global pharmaceutical company. Based in Oxford, UK, Enara Bio is backed by RA Capital, Samsara Biocapital and SV Health Investors. For more information, please visit: www.enarabio.com

Comments and DMs to this account are not monitored, for any further information please head to our website

Related People

Kevin PojasekFounder

United States - Cambridge, Massachusetts

C-level biotech exec with experience founding and leading companies in the US and UK / VC fundraising and biopharma deal-making track record / R&D program leadership ranging from discovery through mid-stage clinical trials / passion for the journey

LinkedIn https://www.linkedin.com/in/kevin-pojasek/